We serve Chemical Name:ethyl 3-(2-bromo-5-methoxyphenyl)propanoate CAS:131819-11-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ethyl 3-(2-bromo-5-methoxyphenyl)propanoate
CAS.NO:131819-11-9
Synonyms:ethyl 3-(2-bromo-5-methoxyphenyl)propanoate
Molecular Formula:C12H15BrO3
Molecular Weight:287.15000
HS Code:2918990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:341.039ºC at 760 mmHg
Density:1.333g/cm3
Index of Refraction:1.523
PSA:35.53000
Exact Mass:286.02000
LogP:2.95340
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like ethyl 3-(2-bromo-5-methoxyphenyl)propanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 3-(2-bromo-5-methoxyphenyl)propanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 3-(2-bromo-5-methoxyphenyl)propanoate Use and application,ethyl 3-(2-bromo-5-methoxyphenyl)propanoate technical grade,usp/ep/jp grade.
Related News: Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. ethyl 3-(2-bromo-5-methoxyphenyl)propanoate manufacturer Two sources familiar with the situation told Reuters that the agency had cleared about 10 million doses. ethyl 3-(2-bromo-5-methoxyphenyl)propanoate supplier Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. ethyl 3-(2-bromo-5-methoxyphenyl)propanoate vendor Two sources familiar with the situation told Reuters that the agency had cleared about 10 million doses. ethyl 3-(2-bromo-5-methoxyphenyl)propanoate factory Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.
